Suppr超能文献

[慢性肾脏病-矿物质和骨异常的新进展。肾移植后慢性肾脏病-矿物质和骨异常的管理:时机、对象及方法?]

[New Developments in CKD-MBD. The management of posttransplant CKD-MBD : When, Who, and How?].

作者信息

Fujii Naohiko

机构信息

Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine University of Pennsylvania, USA.

出版信息

Clin Calcium. 2014 Dec;24(12):1853-9.

Abstract

Chronic kidney disease - mineral and bone disorder (CKD-MBD) in kidney transplant recipients has a complex pathophysiology, which is a combination of carryover of mineral and bone disorder during the dialysis period and dynamic change in bone and mineral metabolism after transplantation. The most important thing is to know that this pathophysiology is a continuum from the early stage of CKD through the dialysis period to the post-transplant period. However, the current treatment approaches among Japanese nephrologists are based on three different categories : nephrologists elaborately treating predialysis patients against end-stage renal disease ; dialysis doctors aggressively coping with their patients' deadly complications ; and transplant doctors concentrating on post-transplant follow-ups for better graft survival. In this article, I would like to explain the pathophysiology of post-transplant CKD-MBD and then to introduce a new role -- that not only transplant doctors, but also dialysis doctors, should play a crucial role in CKD-MBD in the post-transplant period.

摘要

肾移植受者的慢性肾脏病 - 矿物质和骨代谢紊乱(CKD-MBD)具有复杂的病理生理学,它是透析期矿物质和骨代谢紊乱的延续与移植后骨和矿物质代谢动态变化的结合。最重要的是要明白,这种病理生理学是一个从CKD早期到透析期再到移植后期的连续过程。然而,目前日本肾脏病医生的治疗方法基于三个不同类别:肾脏病医生精心治疗终末期肾病的透析前患者;透析医生积极应对患者的致命并发症;移植医生专注于移植后的随访以提高移植物存活率。在本文中,我将解释移植后CKD-MBD的病理生理学,然后介绍一个新的角色——不仅移植医生,而且透析医生,都应在移植后阶段的CKD-MBD中发挥关键作用。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验